Alice Melão,  —

Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma patients. The company has begun the process of submitting a new drug application to the U.S. Food and Drug Administration, which is expected to be…

Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study shows. The findings highlight the need for new treatment approaches that delay disease progression and reduce disease complications among these patients. The study, “…

Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment candidate for newly diagnosed, relapsed or refractory multiple myeloma. Through this partnership, researchers will test clonoSEQ’s ability to both measure minimal residual disease (MRD)…

A new method that selects and isolates malignant myeloma cells based on their size and molecular markers enables more precise detection of chromosomal abnormalities, University of Southern California researchers show. The sensitivity of the approach allows physicians to classify patients based on their risk and to tailor treatment regimens, ultimately…

P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled in a Phase 1 trial show. The three patients received the lowest dose of P-BCMA-101. Based on the findings, the company is now recruiting additional…

A new antibody targeting the BCMA protein — called SEA-BCMA — has shown promising effectiveness and safety results in animal models of multiple myeloma, making it a strong candidate for treating the cancer. The preclinical findings were shown for the first time during the American Association for Cancer Research (AACR)…

Multiple myeloma patients in China may soon have access to an injectable formulation of melphalan, called Evomela, as the China Food and Drug Administration (CFDA) prepares to review CASI Pharmaceutical‘s application requesting its approval. If approved, the therapy will be the only melphalan formulation available for…

The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies will share the…

Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with Revlimid (lenalidomide) and low-dose dexamethasone, compared to treatment with Alkeran (melphalan), prednisone, and thalidomide. Results from the Phase 3 FIRST trial were revealed in the study, “…

PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma, announced Phosplatin Therapeutics, which is developing the potential therapy. Orphan drug status is expected to support and expedite the clinical development…